Delivery Order SPE2DB22D2007-SPE2DB25FJ4RJ
- Not listed
- The Defense Logistics Agency awarded a $39,778.50 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 24, 2025, for the supply of Scemblix 40 mg tablets (60-count units). The contract, which is not set-aside and was competitively awarded, is scheduled for completion by October 16, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $13,259.50 to AmerisourceBergen Drug Corp for the supply of Scemblix 40 mg tablets (60-count units) under a firm fixed-price contract. The order, issued on August 22, 2025, with an ultimate completion date of September 15, 2025, represents a competitively awarded, non-set-aside procurement executed through AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The place of performance is...
- The Defense Logistics Agency awarded a delivery order valued at $26,519.00 to AmerisourceBergen Drug Corp for supply of Scemblix 40 mg tablets (60 count) on September 5, 2025, with completion targeted for September 26, 2025. This firm fixed price, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for 60 tablets of Scemblix 40 mg medication, with a contract ceiling value of $13,259.50. This firm fixed-price delivery order, awarded October 14, 2025, with an ultimate completion date of November 4, 2025, represents a non-competitive set-aside contract issued under DLA's existing procurement framework. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime...
- The Defense Logistics Agency (DLA) awarded a $13,259.50 delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Scemblix 40 mg tablets (60-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of October 3, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 25, 2025, for the supply of Scemblix 40 mg tablets (60-count units) under a firm fixed-price contract with a ceiling value of $53,038.00. The order is non-set-aside and competitively awarded, with an ultimate completion date of October 17, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical...
- The Defense Logistics Agency awarded a delivery order valued at $13,259.50 to AmerisourceBergen Drug Corp for 60 units of Scemblix 40 mg tablets, with an ultimate completion date of August 18, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and represents a single transaction under the company's larger pharmaceutical supply relationship with the federal government. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a major...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Scemblix 40 mg tablets (60-count units) with a contract ceiling value of $39,778.50. This is a firm fixed-price delivery order with no set-aside designation, representing a competitive award to the pharmaceutical distributor. The contract is set to be completed by September 17, 2025, and performance will take place at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a $13,259.50 delivery order to AmerisourceBergen Drug Corp on April 29, 2025, for the supply of Scemblix 40 mg tablets (60-count units) under a firm fixed-price contract. The order, which must be completed by May 20, 2025, represents a competitively awarded, non-set-aside procurement supporting federal medical supply needs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for military...
- The Defense Logistics Agency (DLA) awarded a $13,259.50 delivery order contract to AmerisourceBergen Drug Corp for the supply of Scemblix 40 mg tablets (60-count units) under a firm fixed-price arrangement. The contract, awarded on April 25, 2025, with an ultimate completion date of May 16, 2025, was not set aside for small business concerns and was competitively awarded. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a...
- SPE2DB22D2007Indefinite Delivery Contract
- SPE2DB22D2007-SPE2DB25FJ4RJDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $26,519.00 to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Scemblix 40 mg tablets in quantities of 60 units. This firm fixed-price, competitively awarded contract carries an ultimate completion date of September 26, 2025, with performance taking place at the vendor's corporate office location in Conshohocken, Pennsylvania. The award represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor serving federal medical procurement needs, functions as a critical vendor for military and veteran healthcare systems through this comprehensive IDC vehicle. The prime contract enables the company to supply a broad range of pharmaceutical products and medical commodities to support military healthcare programs globally. Scemblix, a specialty medication, falls within the company's portfolio of brand-name drugs across multiple therapeutic domains that it delivers through the DLA Medical Supply Chain. This delivery order demonstrates AmerisourceBergen's continued role in fulfilling federal pharmaceutical requirements in open competition with no set-aside designation applied.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $26.5k | 9/5/25 |